150 related articles for article (PubMed ID: 23679317)
1. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma.
Bai SB; Chen HX; Bao YX; Luo X; Zhong JJ
Asian Pac J Cancer Prev; 2013; 14(6):3677-80. PubMed ID: 23886164
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
4. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
5. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
Yang LM; Li XH; Bao CF
Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
[TBL] [Abstract][Full Text] [Related]
6. The role of CCNH Val270Ala (rs2230641) and other nucleotide excision repair polymorphisms in individual susceptibility to well-differentiated thyroid cancer.
Santos LS; Gomes BC; Gouveia R; Silva SN; Azevedo AP; Camacho V; Manita I; Gil OM; Ferreira TC; Limbert E; Rueff J; Gaspar JF
Oncol Rep; 2013 Nov; 30(5):2458-66. PubMed ID: 23982724
[TBL] [Abstract][Full Text] [Related]
7. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
8. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
9. Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.
Gastaud L; Saâda-Bouzid E; Le Morvan V; Pourquier P; Ianessi A; Thariat J; Italiano A; Thyss A
Onkologie; 2013; 36(11):670-3. PubMed ID: 24192772
[TBL] [Abstract][Full Text] [Related]
10. Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes.
Abbasi R; Ramroth H; Becher H; Dietz A; Schmezer P; Popanda O
Int J Cancer; 2009 Sep; 125(6):1431-9. PubMed ID: 19444904
[TBL] [Abstract][Full Text] [Related]
11. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.
Yang J; Wang ZG; Cai HQ; Li YC; Xu YL
Asian Pac J Cancer Prev; 2013; 14(8):4595-8. PubMed ID: 24083708
[TBL] [Abstract][Full Text] [Related]
12. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
13. The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.
Zhao YL; Yang LB; Geng XL; Zhou QL; Qin H; Yang L; Dong YZ; Zhong JJ
Pak J Med Sci; 2013 Sep; 29(5):1225-9. PubMed ID: 24353725
[TBL] [Abstract][Full Text] [Related]
14. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
15. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
16. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S
Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541
[TBL] [Abstract][Full Text] [Related]
17. ERCC polymorphisms and prognosis of patients with osteosarcoma.
Li J; Liu S; Wang W; Zhang K; Liu Z; Zhang C; Chen S; Wu S
Tumour Biol; 2014 Oct; 35(10):10129-36. PubMed ID: 25023406
[TBL] [Abstract][Full Text] [Related]
18. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.
Strom SS; Estey E; Outschoorn UM; Garcia-Manero G
Leuk Lymphoma; 2010 Apr; 51(4):598-605. PubMed ID: 20141440
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer.
Zhang XJ; Liu P; Zhu F
Genet Mol Res; 2014 Jan; 13(2):4419-24. PubMed ID: 24615090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
